Release Date: January 31, 2025
Expiration Date: January 31, 2026
Activity Overview
Molecular biomarker testing-informed management is the standard of care for patients with advanced or metastatic non–small cell lung cancer (NSCLC) harboring actionable genomic alterations. In particular, mutations in the ERBB2 gene can predict benefit of HER2-directed therapy in this subset of patients. In this program, 2 experts in the management of lung cancer discuss the current and emerging principles for testing and managing HER2-mutant NSCLC, with a particular focus on novel treatment approaches in development.
Target Audience
This educational initiative will be directed toward global medical oncologists and pulmonologists. This activity will reach the needs of the health care team by fostering collaboration between pulmonologists and medical oncologists in formulating a management plan for patients with NSCLC, SCLC, and LCNEC-L who have targetable mutations.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
1. Identify clinical trial evidence supporting the utility of targeted therapies in the treatment paradigm for patients with HER2-expressed NSCLC.
Jacob Sands, MD
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: Amgen, Harpoon Therapeutics; Consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Gilead Sciences, Lilly, Medtronic, PharmaMar, Sanofi.
Julia Rotow, MD
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: AbbVie, AstraZeneca, BioAtla, Black Diamond, Blueprint Medicines, Duality, Enliven Therapeutics, LOXO Oncology, ORIC Pharmaceuticals, RedCloud Bio, Regeneron, Summit; Consultant: Amgen, AstraZeneca, BioAtla, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Genentech, Guardant Health, Jazz Pharmaceuticals, Johnson & Johnson, Merus, Pfizer, Sanofi-Genzyme, Summit Therapeutics, Takeda; Other: Honoraria: AstraZeneca; Travel: AstraZeneca, Bristol Myers Squibb, Janssen, Johnson & Johnson, Merus.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here